Arch Therapeutics Inc (OTCBB:ARTH) developer company of the AC5 Surgical Hemostatic Device™ for use in controlling fluid loss and bleeding in order to provide safer and faster surgical and interventional care, disclosed that an independent third party received encouraging data from an animal trial. It compared ACS hemostatic activity with a commercially available hemostat having flowable gelatin and combined with thrombin.
In this trial, full thickness sharp wounds were surgically made in rat livers. These are extremely vascularized parenchymal organs, and then either gelatin-thrombin hemostat or AC5™ was applied in order to discontinue the bleeding. After that the time to hemostasis, the time needed to halt bleeding, was measured. The data showed that average TTH after Arch Therapeutics’ ACS application was less than 30 seconds, while the average TTH after gelatin-thrombin hemostat application was over 200% longer.
Arch’s AC5 didn’t require any cold storage and was maintained at room temperature whereas comparative medication needs to be maintained in frozen state during storage. It is a common limitation of several commercial hemostatic agents derived from blood-products. They also need a multi-step preparation process prior to use.
The study group plans to submit the results for publication and at that time additional data would be made available. This trial is one of series of animal studies comparing AC5 with existing hemostatic products used in surgical procedures. Terrence W. Norchi, MD, the CEO said that the management believes that the company’s technology holds significant potential. The data is encouraging as far as performance of AC5 is concerned. Other features of AC5 include simple preparation, ease of use, lack of animal or human sourcing, and room temperature storage.
In last trading session, the stock price of Arch closed flat at $0.230. The trading volume was 532,623 compared to average share volume of 207,498.